Secura Bio, Inc.

AstraZeneca PLC ’s Imfinzi became the second cancer immunotherapy approved for perioperative use in resectable non-small cell lung cancer (NSCLC) on 15 August, despite the US Food and Drug Administrat

History has not been kind to PI3K inhibitors, but Scorpion Therapeutics, Inc. hopes that its mutant-selective PI3Kα inhibitor, STX-478, can do what most drugs in the class have not, which is show th

Dizal (Jiangsu) Pharmaceutical Co., Ltd. has grabbed the world’s first approval, in China, for a Janus kinase 1 (JAK1) inhibitor for the treatment of relapsed or refractory (r/r) peripheral T-cell ly

After years of struggle, Yakult Honsha Co. Ltd. has decided to shrink its oncology portfolio and tighten the focus of its future pharmaceutical business on microbiome-related therapies. The diversi